NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
corporation (the Company), issued a press release providing an
operational update and reporting financial results for the fourth
quarter and year ended December 31, 2016 (“Press Release”). A
copy of the Press Release and the Fourth Quarter and Year End
Financial Results Presentation are attached hereto as Exhibits
99.1 and 99.2, respectively, and are incorporated herein by
reference.
and 99.2 attached hereto is furnished under Item 2.02 of this
report and shall not be deemed to be filed for purposes of
Section 18 of the Securities Exchange Act of 1934 (the Exchange
Act) or otherwise subject to the liabilities of that section, nor
shall be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, regardless of any
general incorporation language in such filing.
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press Release, dated February 28, 2017, entitled
NewLink Genetics Corporation Provides Operational Update and Reports Fourth Quarter, Year End 2016 Financial Results |
|
|
99.2
|
Fourth Quarter and Year End 2016 Financial Results
Presentation |
About NewLink Genetics Corporation (NASDAQ:NLNK)
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer. NewLink Genetics Corporation (NASDAQ:NLNK) Recent Trading Information
NewLink Genetics Corporation (NASDAQ:NLNK) closed its last trading session 00.00 at 15.21 with 398,972 shares trading hands.
